XM does not provide services to residents of the United States of America.

Oncology Institute Inc reports results for the quarter ended in March - Earnings Summary

<html xmlns="http://www.w3.org/1999/xhtml"><head><title>Oncology Institute Inc reports results for the quarter ended in March - Earnings Summary</title></head><body>
  • Oncology Institute Inc TOI.OQ reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended in March. The lone analyst forecast for the quarter was for a loss of 12 cents per share.

  • Revenue rose 24.2% to $94.67 million from a year ago; analysts expected $95.17 million.

  • Oncology Institute Inc's reported EPS for the quarter was a loss of 22 cents​.

  • The company reported a quarterly loss of $19.89 million.

  • Oncology Institute Inc shares had fallen by 43.0% this quarter and lost 55.9% so far this year.


  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.


  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The average consensus recommendation for the healthcare facilities & services peer group is also "strong buy"

Wall Street's median 12-month price target for Oncology Institute Inc is $2.50

This summary was machine generated from LSEG data May 15 at 08:16 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)





Mar. 31 2024




Dec. 31 2023




Sep. 30 2023




Jun. 30 2023





Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.